Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Accured Expenses: 2013-2024

Historic Change in Accured Expenses for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$1.5 million.

  • ImmunityBio's Change in Accured Expenses fell 12.16% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$855,000, marking a year-over-year increase of 95.48%. This contributed to the annual value of -$1.5 million for FY2024, which is 122.54% down from last year.
  • ImmunityBio's Change in Accured Expenses amounted to -$1.5 million in FY2024, which was down 122.54% from $6.7 million recorded in FY2023.
  • ImmunityBio's Change in Accured Expenses' 5-year high stood at $12.5 million during FY2020, with a 5-year trough of -$1.5 million in FY2024.
  • In the last 3 years, ImmunityBio's Change in Accured Expenses had a median value of $4.1 million in 2022 and averaged $3.1 million.
  • In the last 5 years, ImmunityBio's Change in Accured Expenses surged by 205.93% in 2020 and then tumbled by 122.54% in 2024.
  • ImmunityBio's Change in Accured Expenses (Yearly) stood at $12.5 million in 2020, then tumbled by 58.53% to $5.2 million in 2021, then declined by 20.84% to $4.1 million in 2022, then spiked by 63.07% to $6.7 million in 2023, then plummeted by 122.54% to -$1.5 million in 2024.